| Name | Title | Contact Details |
|---|
Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.
Pharmathene, Inc is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RareCyte is a company focused on characterizing and isolating rare cells from blood.